tbuckley/cabot-search huggingface dataset:
Phase II trial of HyperCVAD and Dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia
Authors: Ohad Benjamini, Theresa Liu Dumlao, Hagop Kantarjian, Susan O'Brien, Guillermo Garcia‐Manero, Stefan Faderl, Jeffrey Jorgensen, Rajyalakshmi Luthra, Rebecca Garris, Deborah Thomas, Partow Kebriaei, Richard Champlin, Elias Jabbour, Jan Burger, Jorge Cortes, Farhad Ravandi
Journal: American Journal of Hematology (2013)

Dasatinib is a second generation tyrosine kinase inhibitor, with activity in imatinib resistant Ph-positive ALL.We have treated 34 patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia(ALL) (n519) or lymphoid blast phase of chronic myelogenous leukemia (CML-LB) (n515) with the combination of dasatinib and the hyper CVAD regimen. Prior regimens included hyper CVAD plus imatinib(n511, 4 had transplant in first CR), other combination chemotherapy (n512), monotherapy with kinase inhibitors other than dasatinib (n59), and investigational agents (n52). Pretreatment ABL mutations were noted in 10 patients. The overall response rate was 91%, with 24 patients (71%) achieving complete response(CR), and 7(21%) CR with incomplete platelet recovery (CRp). Two patients died during induction and one had progressive disease. Twenty-six patients (84%) achieved complete cytogenetic remission after one cycle of therapy. Overall, 13 patients (42%) achieved complete molecular response, and 11 patients (35%) had major molecular response (BCR-ABL/ABL<0.1%). Nine patients proceeded to allogeneic transplantation.Grades 3 and 4 toxicities included hemorrhage, pleural and pericardial effusions and infections. The median follow-up for patients with CML-LB is 37.5 months (range, 7–70 months) with a 3-year overall survival of 70%;68% remained in CR at 3 years. For ALL patients, the median follow-up is 52 months (range, 45–59 months)with a 3-year survival of 26%; 30% remain in CR at 3 years. The combination of Hyper CVAD regimen with dasatinib is effective in patients with relapsed Ph-positive ALL and CML-LB.
Abstract 11657: Frequency and Severity of Hypoglycemia in Children With Beta Blocker-Treated Long QT Syndrome
Authors: Joseph T Poterucha, Johan M Bos, Bryan C Cannon, Michael J Ackerman
Journal: Circulation (2014)

Background: Beta-blockers are the treatment of choice for most children with long QT syndrome (LQTS). Hypoglycemia is a known adverse effect of beta-blocker therapy, however, only a few such cases have been reported in the literature in pediatric patients. Here, we determined the frequency and severity of hypoglycemia among children with beta-blocker treated LQTS. Methods: A retrospective electronic medical record review identified 323 children with clinically/genetically diagnosed LQTS on beta-blocker therapy (157 males, average age at diagnosis 8 ± 5 years old, average QTc 470 ± 53 ms, LQT1 in 157, LQT2 in 105, and LQT3 in 13) who were evaluated in Mayo Clinic’s LQTS Clinic from 2000 - 2014. Results: Overall, 10 children (3.1%; 7 males, average QTc 486 ± 35 ms) developed 12 episodes of hypoglycemia (mean initial glucose 19 ± 7 mg/dL) with beta-blocker associated hypoglycemic episodes in 6/105 LQT2 patients (5.7%) and 3/157 LQT1 patients (1.9%, p = 0.16). The mean age at hypoglycemia was 3.5 ± 2 years (r...
Do Back Belts Prevent Back Injury?—Reply
Authors: Stephen W. Marshall
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Routine vs Selective Invasive Strategies in Acute Coronary Syndromes
Authors: Enrique V. Carbajal
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 16775: Body Mass Index Predicts Exercise Capacity in Patients With Hypertrophic Cardiomyopathy
Authors: Caroline A Ball, Carolyn M Larsen, Virginia Hebl, Jeffrey B Geske, Kevin C Ong, Konstantinos C Siontis, Thomas P Olson, Steve R Ommen, Thomas G Allison
Journal: Circulation (2014)

Introduction: Impaired peak VO2 and obesity are known predictors of morbidity and mortality in Hypertrophic Cardiomyopathy (HCM). The purpose of this study is to determine the degree of exercise impairment due to excess weight in patients with HCM. Methods: Adult HCM patients who underwent cardiopulmonary treadmill testing at our tertiary referral center from 2006 - 2012 and had consented to research participation were identified retrospectively. Percent predicted peak VO2 was calculated by the Astrand formula for men and the Jones formula for women which adjust for age and gender. Baseline echocardiographic features obtained within 1 week of exercise testing and % predicted peak VO2 were compared among four groups of patients stratified by body mass index (BMI). Results: 510 patients were identified, with a mean age at diagnosis of 44.3 ± 16.1 years, 186 (36.5%) female. Mean BMI at the time of cardiopulmonary exercise testing was 29.7 ± 5.3 and 227 (44.6%) patients had a BMI ≥ 30. Overweight and obese patients were older and were more likely to be male than their normal weight peers. However, there was no significant difference in ejection fraction (EF), resting left ventricular outflow tract gradient, right ventricular systolic pressure (RVSP), or septal thickness among the groups. HCM patients show impaired peak VO2 across all BMI groups. While peak VO2 increased progressively across BMI groups consistent with greater O2 demand generated by higher body weight, the adjusted peak VO2 in mL/kg/min fell progressively, indicating progressively greater performance impairment with increasing BMI despite similar degrees of cardiac impairment (p &lt;0.0001) (Table 1). Conclusion: Increased BMI is associated with reduced exercise performance in a graded manner in HCM patients independent of cardiac impairment identified on echocardiography.
Alcoholism: A Treatment Guide for General Practitioners.
Authors: Henry Newman
Journal: Annals of Internal Medicine (1959)

This new book should be available to, or in the library of all physicians concerned with diseases and disorders of the bones, joints, and muscles.Each of the fourteen chapters is organized to diagnose and treat specific problems, from congenital defects of the newborn to neoplasms of bone.An excellent outline of symptoms and their most likely cause precedes each new subject.This feature makes quick reference easy.The one hundred and eighty illustrations are sharp, clear, and free of distracting, extraneous matter.The pertinent roentgenograms are clearly reproduced.Helpful estimates of disability periods follow sections on injuries.A refreshing minimum of footnotes, references, and statistical tables, combined with the clear, sharp type makes easy, pleasant reading.Controversial subjects are discussed with tact and restraint.The critical reader should forgive the occasional error in spelling and the frequent use of trade names for common drugs.This book is sincerely recommended to the general prac- titioner and pediatrician.Interns and residents should find it especially helpful.As the authors say in the preface, "by using this book a doctor should be able to arrive at a diagnosis and outline his treatment with a minimum loss of time."
Treatment Outcomes With Rituximab in 100 Patients With Neuromyelitis Optica
Authors: Su-Hyun Kim, In Hye Jeong, Jae-Won Hyun, AeRan Joung, Hyo-Jin Jo, Sang-Hyun Hwang, Sooin Yun, Jungnam Joo, Ho Jin Kim
Journal: JAMA Neurology (2015)

<h3>Importance</h3> Despite the increased use of rituximab therapy in neuromyelitis optica spectrum disorder (NMOSD), the overall efficacy and safety of long-term rituximab treatment in a large group of patients is uncertain. Furthermore, the identification of a predictor of rituximab response is an important issue for assessing the individual risk-benefit of therapy and making treatment decisions. <h3>Objective</h3> To assess the long-term clinical efficacy and safety of rituximab treatment in patients with NMOSD and the influence of fragment c gamma receptor 3A (<i>FCGR3A</i>) polymorphisms on rituximab response. <h3>Design, Setting, and Participants</h3> A retrospective review of 100 patients with relapsing NMOSD treated with rituximab for at least 6 months, from February 1, 2006, to January 31, 2015, at the institutional referral center. After induction therapy, a single infusion of rituximab (375 mg/m<sup>2</sup>) as maintenance therapy was administered whenever a reemergence of CD27<sup>+</sup>memory B cells among peripheral blood mononuclear cells occurred. Using an allele-specific polymerase chain reaction–based method, the gene polymorphisms<i>FCGR3A</i>-V158F were assessed. <h3>Main Outcomes and Measures</h3> The primary end point was annualized relapse rate; disability (Expanded Disability Status Scale score), safety of rituximab treatment, event of insufficient memory B-cell depletion following rituximab, and time to retreatment of rituximab were secondary end points. <h3>Results</h3> By January 31, 2015, a total of 100 patients received repeated rituximab treatment during a median of 67 months. Of these patients, 41 had more than 5 years’ follow-up and 24 had more than 7 years’ follow-up. The annualized relapse rate was reduced significantly by 96% (mean [SD] annualized relapse rate of prerituximab vs postrituximab, 2.4 [2.0] vs 0.1 [0.6]) and disability improved or stabilized in 96% of patients. Rates of adverse events were generally stable. The<i>FCGR3A</i>-F allele was associated with a risk of relapse while receiving rituximab treatment (additive model,<i>P</i> &lt; .05; recessive model,<i>P</i> = .04; maximum,<i>P</i> = .03) and insufficient memory B-cell depletion (additive model,<i>P</i> = .03; recessive model,<i>P</i> = .03; maximum,<i>P</i> = .03). <h3>Conclusions and Relevance</h3> Repeated rituximab treatment for NMOSD was observed in an increasing number of patients and increasing duration of exposure and maintained good efficacy and a safety profile consistent with previous reports. The finding of a relationship between<i>FCGR3A</i>genetic polymorphisms and rituximab response suggests the importance of individualized rituximab treatment strategies in NMOSD.
Abstract 269: How Much Exposure to Resuscitation Do Emergency Medical Services Personnel Get?
Authors: Kylie Dyson, Janet Bray, Karen Smith, Stephen Bernard, Lahn Straney, Judith Finn
Journal: Circulation (2014)

Objectives: The exposure of emergency medical service personnel (paramedics) to out-of-hospital cardiac arrest (OHCA) and resuscitation procedures could be an important factor in skill maintenance and quality of care. This study aims to describe paramedic exposure to OHCA resuscitation in the state of Victoria, Australia (population 5.8 million). Methods: We extracted and linked data from the Victorian Ambulance Cardiac Arrest Registry (VACAR) and Ambulance Victoria’s employment dataset for the period 2003-2012. Paramedics were considered to have ‘exposure’ to OHCA if they attended a case where resuscitation was attempted. Individual rates were calculated for annual exposure (number of OHCA exposures for each paramedic/years employed in study period) and days between exposures (total paramedic days/total number of exposures). Results: Over the 10-year period, there were 49,107 OHCAs and 5,673 paramedics employed. Resuscitation was attempted in 44% of patients. An average of 3.2 (SD±1.1) paramedics attended each case. The median average exposure of paramedics was 2.2 (IQR=1.2-3.5) OHCAs/year. The proportion with no exposures in a year increased from 39% in 2003 to 43% in 2012 (p=0.036). OHCA exposure was significantly less in those employed part-time or casual (p&lt;0.001), in a rural area (p&lt;0.001) or with a lower qualification (p&lt;0.001) (Table). Annual exposure to pediatric and traumatic OHCAs was particularly low (Table). Paramedics were exposed to an average of 0.006 OHCAs/day, meaning it would take an average of 163 days be exposed to OHCA and up to 12.5 years for rare cases, such as pediatric OHCAs. Conclusion: Our study identified paramedic exposure to resuscitation is low and has decreased over time. This highlights the importance of supplementing paramedic exposure with other methods, such as simulation, to maintain resuscitation skills. This may be particularly important to paramedics with low exposure and for rare case types, such as pediatric OHCA.
Retinoic acid is a negative regulator for the differentiation of cord blood-derived human mast cell progenitors
Authors: Tatsuya Kinoshita, Kenichi Koike, Hadija Hemed Mwamtemi, Susumu Ito, Shuichi Ishida, Yozo Nakazawa, Yumi Kurokawa, Kazuo Sakashita, Tsukasa Higuchi, Kouichi Takeuchi, Nobukuni Sawai, Masaaki Shiohara, Takehiko Kamijo, Shigeyuki Kawa, Tetsuji Yamashita, Atsushi Komiyama
Journal: Blood (2000)
Electron Microscopic Examination of the MC1M Tumor. II. A Comparison Between the Sublines M&lt;sub&gt;AA&lt;/sub&gt;, M&lt;sub&gt;AS1&lt;/sub&gt;, and M&lt;sub&gt;SS&lt;/sub&gt;
Authors: A. Bergstrand, N. Ringertz
Journal: JNCI Journal of the National Cancer Institute (1960)
Global Hematopoietic Stem Cell Transplantation (HSCT) At One Million: An Achievement Of Pioneers and Foreseeable Challenges For The Next Decade. A Report From The Worldwide Network For Blood and Marrow Transplantation (WBMT)
Authors: Dietger Niederwieser, Marcelo C Pasquini, Mahmoud D. Aljurf, Dennis L. Confer, Helen Baldomero, Luis Fernando Bouzas, Mary M. Horowitz, Minako Iida, Yoshihisa Kodera, Jeffrey H. Lipton, Machteld Oudshoorn, Eliane Gluckman, Jakob R. Passweg, Jeffrey Szer, Nicolas Novitzky, Jon J. van Rood, Luc Noel, J. Alejandro Madrigal, Karl Frauendorfer, Alois Gratwohl, Frederick R. Appelbaum
Journal: Blood (2013)
A nano-immunoassay system for monitoring targeted drug impact on signaling pathways from small samples of primary hematopoietic malignancies
Authors: Alice Fan, Wilhelm Lachnit, Debabrita Deb-Basu, David Voehringer, Dean Felsher
Journal: Clinical Cancer Research (2007)

C22   Measuring the effect of targeted drug therapy on signal transduction pathways is important for drug development and cancer treatment. Cancer is caused by activation of oncogenes and/or inactivation of tumor suppressor genes. Regulation of many of these oncogenes and tumor suppressor genes occurs through signal transduction pathways which are often the point of intervention of targeted therapeutics. Specific oncogene inhibition can be an effective therapy for cancer, as documented in animal models and in human cancers. Using a mouse model of lymphoma we have previously shown that suppressing the activation of the MYC oncogene induces sustained tumor regression. Here we demonstrate the use of a nano-immunoassay platform (Firefly TM  system) to measure changes in the expression and activation of a variety of onco/signaling proteins. By measuring the response of AKT, ERK, MYC, MEK, STAT and JNK in malignant cells before and after treatment we hypothesize that patterns will be revealed indicative of therapeutic clinical response. The levels of the different proteins were measured with high accuracy and sensitivity in as few as 400 cells. Since this technology separates different phosphorylated forms of a protein based on their isoelectric point, a single pan-specific antibody was able to distinguish between the phosphorylated and non-phosphorylated forms of each protein. Interestingly, we were able to identify an effect of the small-molecule tyrosine kinase inhibitor, Gleevec, on specific isoforms of ERK protein in patients responding to therapy not seen in refractory patients. Hence, this novel technique can measure the levels of key signaling proteins in oncogenic pathways from very small samples. Comparison of this technique was performed with Western blot and phospho-protein FACS analyses. This approach can potentially be used for high throughput analysis of microscopic clinical specimens for biomarker discovery, molecular diagnostics, clinical screening and to monitor changes in signaling during therapeutic interventions.
THE CLINICAL EVALUATION OF SUSTAINED RELEASE ANTITUSSIVES
Authors: L J CASS, W S FREDERIK
Journal: Annals of Internal Medicine (1958)

Article1 July 1958THE CLINICAL EVALUATION OF SUSTAINED RELEASE ANTITUSSIVESLEO J. CASS, M.D., WILLEM S. FREDERIK, M.D.LEO J. CASS, M.D.Search for more papers by this author, WILLEM S. FREDERIK, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-49-1-151 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptINTRODUCTIONIn recent years significant advances have been made in the development of forms of medication which will more effectively provide the patient with the total daily prescribed dose. These newer forms of medication eliminate the necessity of taking doses of medicine at two-, three- or four-hour intervals. The common goal in the development of sustained release preparations is to provide a medication that will be clinically effective with a maximum of one or two oral doses in a 24-hour period. A sustained release preparation is one that will yield predictable amounts of the active component over an extended period...Bibliography1. GelvinMcGavackKenigsberg EPTAS: Sustained release of Dexedrine: a comparison of various preparations in the management of obesity, New York State J. Med. 54: 1340, 1954. MedlineGoogle Scholar2. ChanHays YTEE: A resin complex for prolonged anti-tussive effects, Am. J. M. Sc. 234: 207-212 (Aug.) 1957. CrossrefMedlineGoogle Scholar3. CassFrederik LJWS: Evaluation of new anti-tussive agent, New England J. Med. 249: 132-136, 1953. CrossrefMedlineGoogle Scholar4. CassFrederikAndosca LJWSJB: Quantitative comparison of dextromethorphan hydrobromide and codeine, Am. J. M. Sc. 277: 291, 1954. CrossrefGoogle Scholar5. CassFrederik LJWS: Quantitative comparison of cough-suppressing effects of Romilar and other anti-tussives, J. Lab. and Clin. Med. 48: 879, 1956. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication August 16, 1957.Requests for reprints should be addressed to Leo J. Cass, M.D., Director, Harvard University Law School Health Services, Austin Hall, Cambridge 38, Massachusetts. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byOral Prolonged Action Medicaments: Their Pharmaceutical Control and Therapeutic Aspects3 Antitussive DrugsObesity and pregnancyThe Newer Antitussive AgentsEffective reduction of the acute toxicity of certain pharmacologic agents by use of synthetic ion exchange resinsThe Clinical Investigation of a Codeine Resin Complex 1 July 1958Volume 49, Issue 1Page: 151-160KeywordsTuberculosisUpper respiratory tract infections ePublished: 1 December 2008 Issue Published: 1 July 1958 PDF downloadLoading ...
Unicellular-Unilineage Erythropoietic Cultures: Molecular Analysis of Regulatory Gene Expression at Sibling Cell Level
Authors: Benedikt L. Ziegler, Robert Müller, Mauro Valtieri, Christa P. Lamping, Christian A. Thomas, Marco Gabbianelli, Christina Giesert, Hans-Jörg Bühring, Lothar Kanz, Cesare Peschle
Journal: Blood (1999)
Does My Mother Really Need That Central Line?
Authors: Anton Travis Manasco, Judith A. Linden
Journal: JAMA Internal Medicine (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal